Literature DB >> 24521762

Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging in Japanese hypertrophic cardiomyopathy patients.

Yasuki Hen1, Nobuo Iguchi, Yuko Utanohara, Kaori Takada, Haruhiko Machida, Morimasa Takayama, Tetsuya Sumiyoshi.   

Abstract

BACKGROUND: The prognostic value of late gadolinium enhancement (LGE) on contrast-enhanced cardiovascular magnetic resonance (CMR) in Japanese hypertrophic cardiomyopathy (HCM) patients in a large, single-center cohort was investigated. METHODS AND
RESULTS: A total of 345 HCM patients (mean age, 59±17 years; 214 male) underwent CMR with gadolinium enhancement, and were followed (mean duration, 21.8 months) for cardiovascular events. Patients were divided into event-positive and event-negative groups. The clinical and CMR characteristics were compared between the 2 groups, and predictors of cardiovascular events assessed on multivariate analysis. LGE was positive in 252 patients (73%). The annual cardiovascular events rate was significantly higher in patients with LGE than in those without (6.2%/year vs. 0.6%/year, P=0.003). On multivariate analysis, LGE (hazard ratio [HR], 7.436; 95% confidence interval [CI]: 1.001-55.228, P=0.050), increased myocardial mass index (HR, 1.013; 95% CI: 1.002-1.023, P=0.018), reduced left ventricular ejection fraction (HR, 0.965; 95% CI: 0.945-0.985, P=0.001), and atrial fibrillation (HR, 2.257; 95% CI: 1.024-4.976, P=0.043) were significantly associated with cardiovascular events.
CONCLUSIONS: The presence of LGE, increased myocardial mass index, reduced left ventricular ejection fraction and atrial fibrillation were independent predictors of adverse prognosis in Japanese HCM patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24521762     DOI: 10.1253/circj.cj-13-0979

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  6 in total

1.  Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction.

Authors:  Akira Funada; Hideaki Kanzaki; Teruo Noguchi; Yoshiaki Morita; Yasuo Sugano; Takahiro Ohara; Takuya Hasegawa; Hiromi Hashimura; Hatsue Ishibashi-Ueda; Masafumi Kitakaze; Satoshi Yasuda; Hisao Ogawa; Toshihisa Anzai
Journal:  Heart Vessels       Date:  2015-03-28       Impact factor: 2.037

2.  Feature-tracking cardiac magnetic resonance method: a valuable marker of replacement fibrosis in hypertrophic cardiomyopathy.

Authors:  Nahid Rezaeian; Leila Hosseini; Negar Omidi; Mahya Khaki; Homa Najafi; Kianoosh Kasani; Mostafa Mousavizadeh; Yasaman Khalili; Mohammad Mehdi Hemmati Komasi; Yaser Toloueitabar; Sanaz Asadian
Journal:  Pol J Radiol       Date:  2022-05-16

3.  Prognostic value of cardiovascular magnetic resonance imaging for life-threatening arrhythmia detected by implantable cardioverter-defibrillator in Japanese patients with hypertrophic cardiomyopathy.

Authors:  Yasuki Hen; Mayuko Tsugu-Yagawa; Nobuo Iguchi; Yuko Utanohara; Kaori Takada; Haruhiko Machida; Ayako Takara; Kunihiko Teraoka; Kanki Inoue; Itaru Takamisawa; Morimasa Takayama; Tsutomu Yoshikawa
Journal:  Heart Vessels       Date:  2017-08-01       Impact factor: 2.037

Review 4.  Cardiac magnetic resonance imaging in the evaluation of patients with hypertrophic cardiomyopathy.

Authors:  Juan Carlos Brenes; Adelina Doltra; Susanna Prat
Journal:  Glob Cardiol Sci Pract       Date:  2018-08-12

5.  Patterns of Left Ventricular Hypertrophy and Late Gadolinium Enhancement on Cardiac MRI in Patients with Hypertrophic Cardiomyopathy and their Prognostic Significance - An Experience from a South Asian Country.

Authors:  Fateh Ali Tipoo Sultan; Sheema Saadia
Journal:  J Clin Imaging Sci       Date:  2021-03-04

6.  Predictive Values of N-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin I for Myocardial Fibrosis in Hypertrophic Obstructive Cardiomyopathy.

Authors:  Changlin Zhang; Rong Liu; Jiansong Yuan; Jingang Cui; Fenghuan Hu; Weixian Yang; Yan Zhang; Youzhou Chen; Shubin Qiao
Journal:  PLoS One       Date:  2016-01-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.